Ahmad Harris A, East James E, Panaccione Remo, Travis Simon, Canavan James B, Usiskin Keith, Byrne Michael F
Bristol Myers Squibb, Princeton, NJ, USA.
Translational Gastroenterology Unit, Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
Intest Res. 2023 Jul;21(3):283-294. doi: 10.5217/ir.2023.00020. Epub 2023 Apr 20.
Inflammatory bowel disease encompasses Crohn's disease and ulcerative colitis and is characterized by uncontrolled, relapsing, and remitting course of inflammation in the gastrointestinal tract. Artificial intelligence represents a new era within the field of gastroenterology, and the amount of research surrounding artificial intelligence in patients with inflammatory bowel disease is on the rise. As clinical trial outcomes and treatment targets evolve in inflammatory bowel disease, artificial intelligence may prove as a valuable tool for providing accurate, consistent, and reproducible evaluations of endoscopic appearance and histologic activity, thereby optimizing the diagnosis process and identifying disease severity. Furthermore, as the applications of artificial intelligence for inflammatory bowel disease continue to expand, they may present an ideal opportunity for improving disease management by predicting treatment response to biologic therapies and for refining the standard of care by setting the basis for future treatment personalization and cost reduction. The purpose of this review is to provide an overview of the unmet needs in the management of inflammatory bowel disease in clinical practice and how artificial intelligence tools can address these gaps to transform patient care.
炎症性肠病包括克罗恩病和溃疡性结肠炎，其特征是胃肠道炎症呈失控、复发和缓解的病程。人工智能代表了胃肠病学领域的一个新时代，围绕炎症性肠病患者人工智能的研究数量正在增加。随着炎症性肠病临床试验结果和治疗靶点的不断发展，人工智能可能被证明是一种有价值的工具，可用于提供对内窥镜表现和组织学活性的准确、一致且可重复的评估，从而优化诊断过程并确定疾病严重程度。此外，随着人工智能在炎症性肠病中的应用不断扩展，它们可能为通过预测生物治疗的治疗反应来改善疾病管理以及通过为未来治疗个性化和降低成本奠定基础来完善护理标准提供理想机会。本综述的目的是概述临床实践中炎症性肠病管理方面未满足的需求，以及人工智能工具如何填补这些空白以改变患者护理。
